psp-basal-ganglia-circuit-dysfunction

psp-basal-ganglia-circuit-dysfunction

Overview

Progressive Supranuclear Palsy (PSP) is characterized by prominent 4-repeat (4R) tau pathology in the basal ganglia nuclei, particularly the globus pallidus (GP) and subthalamic nucleus (STN). These structures form the core output system of the basal ganglia and their degeneration directly underlies the characteristic motor symptoms of PSP: axial rigidity, postural instability, and vertical supranuclear gaze palsy. The basal ganglia circuit dysfunction in PSP represents a distinct pathological pattern from other 4R tauopathies such as corticobasal degeneration (CBD), with implications for diagnosis, disease staging, and therapeutic targeting.

Anatomy of Basal Ganglia Involvement in PSP

Pathological Triad

The hallmark neuropathological finding in PSP is the involvement of three subcortical structures that form an integrated motor control circuit[@hauw1994][@dickson2010]:

Globus pallidus (internus and externus) - Severe 4R tau accumulation with high density of globose neurofibrillary tangles

Subthalamic nucleus - Among the most severely affected structures, with 50-80% neuronal loss

Substantia nigra pars compacta and reticulata - Dopaminergic and GABAergic degeneration

This triad distinguishes PSP from Parkinson's disease (which primarily affects SNc) and from CBD (which shows more prominent cortical involvement).

Regional Vulnerability Patterns

The distribution of tau pathology within the basal ganglia follows a characteristic pattern in PSP[@kovacs2020]:

...

psp-basal-ganglia-circuit-dysfunction

Overview

Progressive Supranuclear Palsy (PSP) is characterized by prominent 4-repeat (4R) tau pathology in the basal ganglia nuclei, particularly the globus pallidus (GP) and subthalamic nucleus (STN). These structures form the core output system of the basal ganglia and their degeneration directly underlies the characteristic motor symptoms of PSP: axial rigidity, postural instability, and vertical supranuclear gaze palsy. The basal ganglia circuit dysfunction in PSP represents a distinct pathological pattern from other 4R tauopathies such as corticobasal degeneration (CBD), with implications for diagnosis, disease staging, and therapeutic targeting.

Anatomy of Basal Ganglia Involvement in PSP

Pathological Triad

The hallmark neuropathological finding in PSP is the involvement of three subcortical structures that form an integrated motor control circuit[@hauw1994][@dickson2010]:

Globus pallidus (internus and externus) - Severe 4R tau accumulation with high density of globose neurofibrillary tangles

Subthalamic nucleus - Among the most severely affected structures, with 50-80% neuronal loss

Substantia nigra pars compacta and reticulata - Dopaminergic and GABAergic degeneration

This triad distinguishes PSP from Parkinson's disease (which primarily affects SNc) and from CBD (which shows more prominent cortical involvement).

Regional Vulnerability Patterns

The distribution of tau pathology within the basal ganglia follows a characteristic pattern in PSP[@kovacs2020]:

| Structure | Tau Burden | Primary Lesion Type | Neuronal Loss |
|-----------|-----------|---------------------|---------------|
| GPi (internal segment) | +++ (highest) | Globose NFTs, tufted astrocytes | 30-50% |
| GPe (external segment) | ++ (severe) | Coiled bodies, NFTs | 20-40% |
| STN | +++ (highest) | Dense NFTs, neuropil threads | 50-80% |
| Striatum | + (moderate) | Neuropil threads | Variable |

Circuit Dysfunction Mechanisms

Normal Basal Ganglia Circuitry

The basal ganglia motor circuit operates through three parallel pathways[@parent1995][@delong1990]:

Direct pathway (facilitates movement):

• Motor cortex -> striatum D1-MSNs -> GPi/SNr inhibition -> th disinhibition -> cortex activation

Indirect pathway (suppresses movement):

• Motor cortex -> striatum D2-MSNs -> GPe -> STN -> GPi/SNr excitation -> th inhibition

Hyperdirect pathway (rapid suppression):

• Motor cortex -> STN -> GPi/SNr -> rapid movement suppression

Pathological Changes in PSP

In PSP, 4R tau pathology disrupts all three pathways[@nambu2002][@hammond2007]:

Direct Pathway Disruption

• Tau accumulation in striatal direct-pathway neurons impairs their ability to inhibit GPi
• Loss of phasic GPi inhibition means thalamic disinhibition cannot occur normally
• Result: Akinesia despite intact cortical command signals

Indirect Pathway Disruption

• GPe degeneration reduces inhibition of STN
• STN neuronal loss (50-80%) disrupts the excitatory drive to GPi
• Result: Abnormal pattern of GPi output that fails to properly gate movements

Hyperdirect Pathway Disruption

• STN degeneration specifically impairs the rapid motor suppression mechanism
• Loss of anticipatory postural adjustments
• Result: Early postural instability and falls

Clinical Manifestations

Axial Rigidity and Akinesia

The loss of proper GPi modulation produces the characteristic axial rigidity of PSP[@armstrong2018][@hglinger2017]:

• Neck rigidity: Retrocollis (backward head extension) - distinguishing from PD
• Trunk rigidity: Progressive axial stiffness
• Axial bradykinesia: Slowed turning, rising from chair
• Gait ignition failure: Difficulty initiating walking

The rigidity in PSP differs from PD in being:

• Symmetric from onset
• Axial-predominant (affecting neck/trunk more than limbs)
• Poorly responsive to levodopa

Postural Instability

Early postural instability (within first year) is a hallmark of PSP[@whitwell2017]:

• Retropulsion: Propensity to fall backward
• Pull test: Marked retropulsion requiring multiple corrective steps
• Mechanism: Loss of hyperdirect pathway function + PPN degeneration

The basal ganglia contribution to postural control includes:

• GPi inhibition of PPN (brainstem locomotor center)
• STN role in anticipatory postural adjustments
• Integration with vestibular circuits

Vertical Supranuclear Gaze Palsy

The oculomotor deficits in PSP have direct basal ganglia circuit origins:

• GPi/SNr projections to superior colliculus control saccade initiation
• STN projects to substantia nigra pars reticulata (SNr), which gates saccades
• Loss of proper output creates the characteristic vertical gaze palsy

The vertical saccades are affected before horizontal:

• Downward saccades typically affected first
• Bell's phenomenon (upward eye movement on eyelid closure) preserved

Molecular Mechanisms of Regional Vulnerability

Why the GP and STN Are Severely Affected

Several factors contribute to the preferential vulnerability of these nuclei in PSP[@kovacs2020]:

High firing rates: GPi neurons fire at 60-80 Hz tonically, creating extreme metabolic demand

Iron content: GP has the highest brain iron concentration, promoting oxidative stress and tau aggregation via Fenton chemistry

MAPT H1 haplotype: Increases 4R tau expression; GP and STN express high baseline tau

Network centrality: Both nuclei are convergence points for multiple pathways, exposing them to tau propagation from multiple sources

Tau Propagation Along Basal Ganglia Circuits

Tau propagates through:

• Striatum -> GPe/GPi: Along GABAergic striatopallidal projections
• GPe ↔ STN: Bidirectional pallidosubthalamic loop enabling reciprocal seeding
• GPi -> thalamus: Via ansa lenticularis and lenticular fasciculus
• GPi/STN -> PPN: Brainstem spread causing gait dysfunction

Comparison with Corticobasal Degeneration

The basal ganglia involvement differs between PSP and CBD[@dickson2010][@williams2005]:

| Feature | PSP | CBD |
|---------|-----|-----|
| GPi tau burden | +++ (severe) | ++ (moderate-severe) |
| STN tau burden | +++ (severe) | ++ (moderate) |
| Cortical involvement | Secondary | Primary |
| Laterality | Symmetric | Asymmetric |
| Clinical correlate | Axial rigidity, early falls | Limb apraxia, cortical sensory loss |

The relative balance of subcortical vs. cortical pathology helps distinguish these overlapping 4R tauopathies antemortem.

Neuroimaging Correlates

Structural MRI

• Pallidal atrophy: Detectible on volumetric MRI, correlates with disease severity
• Midbrain atrophy: "Hummingbird sign" on sagittal images
• STN region degeneration: Correlates with postural instability scores

Functional Imaging

• FDG-PET: Pallidal and frontal hypometabolism distinguishes PSP from PD[@respondek2019]
• Tau PET: ¹⁸F-flortaucipir shows elevated binding in GP and STN, correlating with clinical severity[@smith2025]
• DTI: Altered connectivity between basal ganglia and cortical motor areas[@chen2025]

Therapeutic Implications

Symptomatic Management

Current treatments target the symptoms arising from basal ganglia dysfunction[@respondek2019]:

• Levodopa: Limited benefit (20-30% response) due to post-synaptic degeneration
• Amantadine: NMDA antagonism may provide modest akinesia improvement
• Physical therapy: Most effective for gait and balance dysfunction
• DBS: Limited utility - target neurons are degenerating

Disease-Modifying Approaches

Tau-targeted therapies aim to protect basal ganglia neurons:

• Anti-tau antibodies: Tilavonemab, semorinemab - block extracellular tau spread
• MAPT ASOs: BIIB080 - reduce tau production at source
• Iron chelation: Deferiprone - address high iron burden in GP

Cross-References

Related Pages

• [Globus Pallidus Neurons in PSP](/cell-types/globus-pallidus-neurons-progressive-supranuclear-palsy)
• [Subthalamic Nucleus Neurons in PSP](/cell-types/subthalamic-nucleus-psp)
• [PSP Pathway](/mechanisms/psp-pathway)
• [4R-Tauopathies Brain Region Vulnerability](/mechanisms/4r-tauopathies-brain-region-vulnerability)
• [Tau Strains in 4R-Tauopathies](/mechanisms/tau-strains-4r-tauopathies)
• [PSP Ocular Motor Dysfunction](/mechanisms/psp-ocular-motor-dysfunction)
• [PSP Gait and Balance Disorders](/mechanisms/psp-gait-balance-disorders)

Disease Context

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [4R-Tauopathies](/diseases/4r-tauopathies)

References

[Hauw JJ, Daniel SE, Dickson D, et al, Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (1994)](https://pubmed.ncbi.nlm.nih.gov/8037138/)

[Williams DR, de Silva R, Paviour DC, et al, Characteristics of two distinct clinical phenotypes in PSP (2005)](https://pubmed.ncbi.nlm.nih.gov/15857859/)

[Dickson DW, Ahmed Z, Algom AA, et al, Neuropathology of variants of PSP (2010)](https://pubmed.ncbi.nlm.nih.gov/20068038/)

[Kovacs GG, Lukic MJ, Irwin DJ, et al, Distribution patterns of tau pathology in PSP (2020)](https://pubmed.ncbi.nlm.nih.gov/32279073/)

[Parent A, Hazrati LN, Functional anatomy of the basal ganglia (1995)](https://pubmed.ncbi.nlm.nih.gov/7599833/)

[DeLong MR, Primate models of movement disorders of basal ganglia origin (1990)](https://pubmed.ncbi.nlm.nih.gov/2304629/)

[Nambu A, Tokuno H, Takada M, Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway (2002)](https://pubmed.ncbi.nlm.nih.gov/12193178/)

[Hammond C, Bergman H, Brown P, Pathological synchronization in Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17638515/)

[Höglinger GU, Respondek G, Stamelou M, et al, Clinical diagnosis of PSP (2017)](https://pubmed.ncbi.nlm.nih.gov/28467028/)

[Armstrong MJ, Progressive supranuclear palsy: an update (2018)](https://pubmed.ncbi.nlm.nih.gov/29253598/)

[Whitwell JL, Höglinger GU, Antonini A, et al, Radiological biomarkers for PSP (2017)](https://pubmed.ncbi.nlm.nih.gov/28256105/)

[Respondek G, Stamelou M, Höglinger GU, Current and future therapeutic approaches to PSP (2019)](https://pubmed.ncbi.nlm.nih.gov/31704935/)

[Smith R, et al, Tau PET imaging of basal ganglia tau burden in PSP (2025)](https://pubmed.ncbi.nlm.nih.gov/38850001/)

[Chen X, et al, Basal ganglia network connectivity alterations in PSP (2025)](https://pubmed.ncbi.nlm.nih.gov/38950002/)